MCID: ORL015
MIFTS: 49

Oral Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Oral Squamous Cell Carcinoma

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 11 19 75 14 16
Squamous Cell Carcinoma of Mouth 71
Mouth Squamous Cell Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0050866
UMLS 71 C0585362

Summaries for Oral Squamous Cell Carcinoma

GARD: 19 A squamous cell carcinoma arising from the oral cavity. It affects predominantly adults in their fifth and sixth decades of life and is associated with alcohol and tobacco use. Human papillomavirus is present in approximately half of the cases. It is characterized by a tendency to metastasize early to the lymph nodes. When the tumor is small, patients are often asymptomatic. Physical examination may reveal erythematous or white lesions or plaques. The majority of patients present with signs and symptoms of locally advanced disease including mucosal ulceration, pain, difficulty with speaking, chewing, and swallowing, bleeding, weight loss, and neck swelling. Patients may also present with swollen neck lymph nodes without any symptoms from the oropharyngeal tumor. The most significant prognostic factors are the size of the tumor and the lymph nodes status.

MalaCards based summary: Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and tongue squamous cell carcinoma. An important gene associated with Oral Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is ncRNAs involved in STAT3 signaling in hepatocellular carcinoma. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, myeloid and skin.

Disease Ontology: 11 An oral cavity cancer that has material basis in squamous cells.

Wikipedia: 75 Squamous-cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Related Diseases for Oral Squamous Cell Carcinoma

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.7 UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
2 tongue squamous cell carcinoma 32.0 UCA1 MIR21 MIR193A MALAT1
3 tongue carcinoma 31.9 MIR21 MIR100 MALAT1
4 esophageal cancer 31.8 UCA1 MIR21 MIR193A MIR100 MALAT1 HOTAIR
5 melanoma 31.8 UCA1 MIR21 MIR193A MIR137 MIR100 MALAT1
6 ovarian cancer 31.6 UCA1 TUG1 NEAT1 MIR21 MIR193A MIR100
7 lung cancer susceptibility 3 31.6 TUG1 MIR21 MIR193A MALAT1 HOTAIR H19
8 esophagus squamous cell carcinoma 31.6 TUG1 MALAT1 HOTAIR CCAT1
9 lung cancer 31.6 UCA1 TUG1 NEAT1 MIR21 MIR193A MIR137
10 nasopharyngeal carcinoma 31.5 NEAT1 MIR21 MIR193A MIR100 MALAT1 HOTAIR
11 hepatocellular carcinoma 31.5 UCA1 TUG1 NEAT1 MIR21 MIR193A MIR137
12 pancreatic cancer 31.2 UCA1 TUG1 NEAT1 MIR21 MIR100 MALAT1
13 retinitis pigmentosa 11 31.2 UCA1 TUG1 NEAT1 MIR193A HOTAIR CCAT2
14 pancreatic ductal adenocarcinoma 31.2 UCA1 MIR21 MIR193A MALAT1 HOTAIR H19
15 leukemia, acute myeloid 31.2 UCA1 TUG1 MIR21 MIR193A MALAT1 HOTAIR
16 cervical cancer 31.2 UCA1 TUG1 NEAT1 MIR21 MIR193A MALAT1
17 gastric cancer 31.1 UCA1 TUG1 NEAT1 MIR21 MALAT1 LINC00668
18 osteogenic sarcoma 31.1 UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
19 bladder cancer 31.1 UCA1 TUG1 MIR21 MIR100 MALAT1 HOTAIR
20 endometrial cancer 31.1 UCA1 TUG1 NEAT1 MIR21 MIR193A HOTAIR
21 kidney cancer 31.0 MIR21 MIR193A MALAT1 HOTAIR H19
22 pharynx cancer 31.0 MIR21 MIR193A MIR100
23 laryngeal squamous cell carcinoma 30.8 NEAT1 MIR21 MALAT1 HOTAIR H19 CCAT1
24 thyroid carcinoma 30.8 UCA1 NEAT1 MALAT1 HOTAIR H19
25 thyroid cancer, nonmedullary, 1 30.8 NEAT1 MALAT1 HOTAIR H19
26 lung squamous cell carcinoma 30.7 TUG1 MIR193A CCAT2 CCAT1
27 glioblastoma 30.7 TUG1 MIR21 MIR137 MALAT1 HOTAIR H19
28 pre-eclampsia 30.6 TUG1 MALAT1 HOTAIR H19
29 leukemia, chronic myeloid 30.3 UCA1 MIR193A HOTAIR H19
30 lip and oral cavity cancer 11.5
31 squamous cell carcinoma, head and neck 11.2
32 leukoplakia 11.2
33 oral leukoplakia 11.1
34 head and neck cancer 11.1
35 lichen planus 11.0
36 oral lichen planus 10.9
37 oral submucous fibrosis 10.9
38 papilloma 10.9
39 conotruncal heart malformations 10.8
40 down syndrome 10.8
41 keratoacanthoma 10.7
42 oral cavity cancer 10.7
43 verrucous carcinoma 10.7
44 oculopharyngeal muscular dystrophy 10.7
45 mucositis 10.7
46 periodontitis 10.7
47 severe combined immunodeficiency 10.6
48 hypereosinophilic syndrome 10.6
49 b-cell lymphoma 10.6
50 renal cell carcinoma, nonpapillary 10.6 UCA1 TUG1 MIR21 MIR193A MIR100 MALAT1

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 5702198 441203
2
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
3
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
4
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
5 Antioxidants Phase 3
6 Protective Agents Phase 3
7 Antimetabolites Phase 2, Phase 3
8 Immunosuppressive Agents Phase 2, Phase 3
9 Immunologic Factors Phase 2, Phase 3
10
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
11
Cetuximab Approved Phase 2 205923-56-4
12 Raspberry Approved Phase 1, Phase 2
13
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
14
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
15
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
16
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
17
Nimotuzumab Investigational Phase 2 780758-10-3
18 Antimitotic Agents Phase 2
19 Tubulin Modulators Phase 2
20 Albumin-Bound Paclitaxel Phase 2
21 Antineoplastic Agents, Immunological Phase 2
22 Immunoglobulins Phase 2
23 Antibodies, Monoclonal Phase 2
24 Antibodies Phase 2
25 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
26 Pharmaceutical Solutions Phase 1, Phase 2
27 Protein Kinase Inhibitors Phase 2
28 Antirheumatic Agents Phase 2
29 Cyclooxygenase Inhibitors Phase 2
30 Cyclooxygenase 2 Inhibitors Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2
32 Analgesics, Non-Narcotic Phase 2
33 Anti-Inflammatory Agents Phase 2
34 Analgesics Phase 2
35 Mitogens Phase 2
36
Rivoceranib Investigational Phase 1 811803-05-1 11315474
37 Immune Checkpoint Inhibitors Phase 1
38
Carbamide peroxide Approved 124-43-6
39
Licorice Approved Early Phase 1
40
Phenol Approved, Experimental Early Phase 1 108-95-2 996
41
Capsaicin Approved 404-86-4 1548943
42
Pembrolizumab Approved 1374853-91-4 254741536
43
Dimenhydrinate Approved 523-87-5 10660
44
Arginine Approved, Investigational, Nutraceutical 74-79-3 6322
45
Phenethyl Isothiocyanate Investigational 2257-09-2 16741
46 Antiviral Agents Early Phase 1
47 Anti-Bacterial Agents Early Phase 1
48 Antimalarials Early Phase 1
49 Anti-Infective Agents
50 Complement System Proteins

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT04137627 Phase 3 Melatonin 20 MG Oral Capsule;Placebo oral capsule
2 Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
3 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Completed NCT00964977 Phase 3
4 Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin Versus Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma Recruiting NCT05125055 Phase 2, Phase 3 Toripalimab (anti-programmed death-1 inhibitor);Albumin paclitaxel;Cisplatin;Docetaxel;5-Fluorouracil
5 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Recruiting NCT04333537 Phase 2, Phase 3 Imaging Agent
6 Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer Unknown status NCT02739204 Phase 2 Celecoxib
7 Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma Completed NCT03502148 Phase 1, Phase 2 PRV111 (Cisplatin Transmucosal System)
8 A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
9 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
10 Neoadjuvant Personalized Anti-PD-1 Therapy With Combination of Anti-VEGFR Therapy in Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Randomized Controlled Phase II Trial Recruiting NCT05069857 Phase 2 Camrelizumab (anti-PD-1 inhibitor);Apatinib (anti-VEGFR inhibitor)
11 A Phase II, Prospective, Single-center, Randomized, Controlled Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma Recruiting NCT04367909 Phase 2 Nimotuzumab;Docetaxel;Carboplatin
12 Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Recruiting NCT04718415 Phase 2 sintilimab, paclitaxel, carboplatin
13 A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
14 Camrelizumab Plus Docetaxel and Cisplatin as First-line Therapy in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE): an Open-label, Single-arm, Phase II Trial Recruiting NCT05611463 Phase 2 Camrelizumab Plus Docetaxel and Cisplatin
15 Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Reduction of Cycles of Chemotherapy, as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Recruiting NCT05098119 Phase 2 Sintilimab, Nab-paclitaxel, Carboplatin;Sintilimab
16 GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial Recruiting NCT02285530 Phase 2 TPF induction chemotherapy
17 A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma Recruiting NCT02285543 Phase 2 TPF induction chemotherapy
18 Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial Recruiting NCT02290145 Phase 2 TPF group
19 A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma Active, not recruiting NCT04649476 Phase 2 Camrelizumab;Camrelizumanb plus TPF
20 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
21 Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma Completed NCT00009841 Phase 1 DC-cholesterol liposome
22 Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC): A Phase I Trial Active, not recruiting NCT04413214 Phase 1 Carrimycin
23 Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial Active, not recruiting NCT04473716 Phase 1 Toripalimab;Paclitaxcel;Cisplatin
24 Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial Active, not recruiting NCT04393506 Phase 1 Camrelizumab;Apatinib
25 Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma Unknown status NCT01987934
26 Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study Unknown status NCT03345966
27 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Unknown status NCT03418454
28 Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line Unknown status NCT03619304
29 Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma Unknown status NCT01587573
30 A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer. Unknown status NCT01772706
31 Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma-A Prospective Multicenter Randomized Controlled Study Unknown status NCT01334320
32 The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Unknown status NCT01946230
33 Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line Unknown status NCT03292822 Early Phase 1 Paclitaxel
34 The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Unknown status NCT02009852
35 Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma Unknown status NCT03877159
36 Myeloid-derived Suppressor Cells (MDSCs) Detection Before and After Beta-glucan Administration in Oral Squamous Cell Carcinoma Patients Unknown status NCT04387682
37 SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck Unknown status NCT00571883
38 The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Unknown status NCT00173849
39 Verification of Saliva MMP-1 as a Strong Diagnostic Marker of Oral Cavity Cancer Completed NCT05049408
40 Fluorescent Visualization in Early Oral Cancer Completed NCT02306967
41 Molecular Mechanisms of Precancerous and Cancerous Lesions of the Oral Cavity Completed NCT03026361
42 Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma Completed NCT03554967
43 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
44 Modern Hybrid Imaging for Staging and Monitoring Patients With Oral Squamous Cell Carcinoma Completed NCT04280159
45 Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study) Completed NCT03109457
46 Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma. Completed NCT02323672
47 A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma Completed NCT01465776
48 Survival Analysis of Segmental Mandibulectomy With Immediate Vascularized Fibula Flap Reconstruction in Stage IV Oral Squamous Cell Carcinoma Patients Completed NCT04967638
49 A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer Completed NCT01314755
50 Ultrasound in Oral Tongue Cancer- Measurement of Depth of Invasion and Intraoperative Help in the Resection Completed NCT04059861

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

Anatomical Context for Oral Squamous Cell Carcinoma

Organs/tissues related to Oral Squamous Cell Carcinoma:

MalaCards : Lymph Node, Myeloid, Skin, Tongue, Bone Marrow, Bone, Endothelial

Publications for Oral Squamous Cell Carcinoma

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 12521)
# Title Authors PMID Year
1
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. 62 46
19396866 2009
2
The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. 62 46
19435529 2009
3
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. 62 46
18381414 2008
4
Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. 46
18946016 2008
5
The role of circular RNAs in the pathophysiology of oral squamous cell carcinoma. 62
36474750 2023
6
Chronic restraint stress promotes the tumorigenic potential of oral squamous cell carcinoma cells by reprogramming fatty acid metabolism via CXCL3 mediated Wnt/β-catenin pathway. 62
36343679 2023
7
[Retracted] MicroRNA‑655 suppresses cell proliferation and invasion in oral squamous cell carcinoma by directly targeting metadherin and regulating the PTEN/AKT pathway. 62
36382654 2023
8
Evaluation of Immunoexpression of AJUBA Protein in Normal Oral Mucosa and Oral Squamous Cell Carcinoma. 62
36222508 2023
9
Mouse Models of Tumor Bone Metastasis and Invasion for Studying CCN Proteins. 62
36370362 2023
10
Notum leads to potential pro-survival of OSCC through crosstalk between Shh and Wnt/β-catenin signaling via p-GSK3β. 62
36280040 2022
11
Geniposide inhibits cell proliferation and migration in human oral squamous carcinoma cells via AMPK and JNK signaling pathways. 62
36382092 2022
12
Early-onset oral cancer as a clinical entity: aetiology and pathogenesis. 62
35487818 2022
13
Oncological outcomes of compartmental surgery and wide local excision in oral tongue and floor of the mouth cancer. 62
36306673 2022
14
Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment. 62
34609700 2022
15
Prognostic Relevance of Lymphatic Vessel Density in Squamous Cell Carcinomas of the Oral Cavity: A Systematic Review and Meta-Analysis. 62
35904748 2022
16
Evaluation of Expression Of ADAM 10 as a Predictor of Lymph Node Metastasis in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. 62
35771404 2022
17
Significance of nuclear EGFR and ABCG2 expression in malignant transformation of oral potentially malignant disorders. 62
36325600 2022
18
Prognostic impact of autoimmune disease in oral cavity squamous cell carcinoma. 62
35870114 2022
19
Systemic conditions associated with increased risk to develop oral squamous cell carcinoma: Systematic review and meta-analysis. 62
36114663 2022
20
Combining radiation therapy with zoledronate for the treatment of osteo-invasive feline oral squamous cell carcinoma. 62
35561080 2022
21
Effect of low-level light therapy before radiotherapy in oral squamous cell carcinoma: An in vitro study. 62
36001245 2022
22
Influence of tumor cell-derived TGF-β on macrophage phenotype and macrophage-mediated tumor cell invasion. 62
36343916 2022
23
Overexpression of gamma glutamyl hydrolase predicts extranodal extension in squamous cell carcinoma of the oral cavity. 62
36229363 2022
24
Variability in Depth of Invasion Measurements in Carcinomas of the Oral Cavity and the Effect on Pathologic Tumor Staging. 62
35499641 2022
25
NEDD4L inhibits glycolysis and proliferation of cancer cells in oral squamous cell carcinoma by inducing ENO1 ubiquitination and degradation. 62
35316145 2022
26
An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma. 62
36381653 2022
27
The long non-coding RNA MEG3 inhibits oral squamous cell carcinoma progression via GATA3. 62
36468944 2022
28
Potential use of salivary mRNA-based biomarkers to predict oral squamous cell carcinoma. 62
36274347 2022
29
Author Correction: Oral Squamous Cell Carcinoma Frequency in Young Patients from Referral Centers Around the World. 62
36239868 2022
30
MicroRNA-382-5p Promotes Oral Squamous Cell Carcinoma Development and Progression by Negatively Regulating PTEN Expression. 62
36162436 2022
31
Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma. 62
35713706 2022
32
Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma. 62
36444617 2022
33
MF-094 nanodelivery inhibits oral squamous cell carcinoma by targeting USP30. 62
36474192 2022
34
Circular RNA_0076977 contributes to oral squamous cell carcinoma progression through mediating microRNA-802 axis. 62
36265392 2022
35
GATA6 regulates expression of annexin A10 (ANXA10) associated with epithelial-mesenchymal transition of oral squamous cell carcinoma. 62
36265396 2022
36
Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series. 62
36311685 2022
37
IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma. 62
36463324 2022
38
Exosomal long noncoding RNAs MAGI2-AS3 and CCDC144NL-AS1 in oral squamous cell carcinoma development via the PI3K-AKT-mTOR signaling pathway. 62
36401978 2022
39
Comparison of tobacco and alcohol consumption in young and older patients with oral squamous cell carcinoma: a systematic review and meta-analysis. 62
36131100 2022
40
Unfolded protein response is involved in the metabolic and apoptotic regulation of oral squamous cell carcinoma. 62
35791990 2022
41
N6-methyladenosine (m6A) reader IGF2BP2 stabilizes HK2 stability to accelerate the Warburg effect of oral squamous cell carcinoma progression. 62
35763110 2022
42
CDH3 is associated with poor prognosis by promoting the malignancy and chemoresistance in oral squamous cell carcinoma. 62
35305877 2022
43
Elucidating the genetic landscape of oral leukoplakia to predict malignant transformation. 62
36449687 2022
44
Development of Silver nanoparticles green-formulated by ‎Matricaria chamomilla as novel chemotherapeutic nanoformulation for the treatment of oral squamous cell carcinoma‎. 62
36397627 2022
45
Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target. 62
35918593 2022
46
Effect of benzo[a]pyrene on proliferation and metastasis of oral squamous cell carcinoma cells: A transcriptome analysis based on RNA-seq. 62
35870112 2022
47
Therapeutic nature of microRNAs in Oral Squamous Cell Carcinoma (OSCC). 62
36067592 2022
48
Spindle and kinetochore-associated complex 3 promotes cell growth via the PI3K/AKT/GSK3β and PI3K/AKT/FOXO1 pathways and is a potential prognostic biomarker for oral squamous cell carcinoma. 62
36123287 2022
49
KDM3A promotes oral squamous cell carcinoma cell proliferation and invasion via H3K9me2 demethylation-activated DCLK1. 62
36094735 2022
50
Gene network analysis of the transcriptome impact of methylated microRNAs on oral squamous cell carcinoma. 62
35951628 2022

Variations for Oral Squamous Cell Carcinoma

Cosmic variations for Oral Squamous Cell Carcinoma:

8 (show top 50) (show all 195)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 10
2 COSM142560281 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
3 COSM144087106 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 10
4 COSM144310203 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
5 COSM142837352 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
6 COSM145017657 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
7 COSM105620276 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
8 COSM143156843 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 10
9 COSM122271559 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 10
10 COSM106053189 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
11 COSM143370869 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
12 COSM111758576 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
13 COSM112253622 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
14 COSM93183630 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
15 COSM144013367 TP53 skin,neck,carcinoma,squamous cell carcinoma c.710G>A p.R237Q 17:7674220-7674220 10
16 COSM144651115 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
17 COSM87898351 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
18 COSM121875983 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 10
19 COSM122734176 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 10
20 COSM133256111 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1040C>T p.S347F 9:99146601-99146601 10
21 COSM97906895 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1016C>T p.S339F 9:99146601-99146601 10
22 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 10
23 COSM97922732 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 10
24 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 10
25 COSM98728167 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 10
26 COSM107058787 RARA skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.P365S 17:40356221-40356221 10
27 COSM98724263 RARA skin,neck,carcinoma,squamous cell carcinoma c.1432C>T p.P478S 17:40356221-40356221 10
28 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 10
29 COSM98707797 RARA skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 10
30 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 10
31 COSM133940534 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 10
32 COSM107373333 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 10
33 COSM130526023 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 10
34 COSM96948694 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
35 COSM97161923 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
36 COSM96619514 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
37 COSM97161935 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10
38 COSM144156675 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.473G>A p.G158E 20:42352227-42352227 10
39 COSM96619533 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10
40 COSM93273665 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10
41 COSM96721565 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
42 COSM96835332 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
43 COSM142597931 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.454C>T p.S152L 20:42352239-42352239 10
44 COSM144156682 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.461C>T p.S154L 20:42352239-42352239 10
45 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
46 COSM96835350 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10
47 COSM96721578 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10
48 COSM96948708 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10
49 COSM93273656 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 10
50 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 10

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

6 (show top 50) (show all 164)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 58782 11 69471367 69490165 Amplification LTO1 Oral squamous cell carcinoma
6 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
7 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
8 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
9 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
10 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
11 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
12 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
13 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
14 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
15 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
16 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
17 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
18 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
19 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
20 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
21 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
22 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
23 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
24 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
25 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
26 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
27 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
28 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
29 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
30 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
31 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
32 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
33 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
34 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
35 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
36 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
37 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
38 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
39 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma
40 116098 17 62600000 70900000 Deletion Oral squamous cell carcinoma
41 121461 18 43500000 53800000 Deletion Oral squamous cell carcinoma
42 121864 18 48200000 53800000 Deletion Oral squamous cell carcinoma
43 122810 18 61600000 73100000 Deletion Oral squamous cell carcinoma
44 141367 2 209000000 221500000 Deletion Oral squamous cell carcinoma
45 141699 2 215300000 221500000 Deletion Oral squamous cell carcinoma
46 158362 21 31500000 35800000 Deletion Oral squamous cell carcinoma
47 163225 22 25900000 37600000 Deletion Oral squamous cell carcinoma
48 166065 3 1 16400000 Deletion Oral squamous cell carcinoma
49 166126 3 1 8700000 Deletion Oral squamous cell carcinoma
50 166139 3 1 91000000 Noncopy numberrandom LOH Oral squamous cell carcinoma

Expression for Oral Squamous Cell Carcinoma

Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for Oral Squamous Cell Carcinoma

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.88 UCA1 MIR21

GO Terms for Oral Squamous Cell Carcinoma

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.28 NEAT1 MIR21 MIR137 MIR100 H19

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 9.65 NEAT1 MIR21 MIR193A MIR137 MIR100 H19
2 negative regulation of superoxide dismutase activity GO:1901670 8.62 MIR21 H19

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.26 MIR21 MIR193A MIR137 MIR100
2 mRNA base-pairing translational repressor activity GO:1903231 8.92 MIR21 MIR193A MIR137 MIR100

Sources for Oral Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....